Drawing for ONCO/RESOLVE

USPTO serial 87619641

ONCO/RESOLVE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
ALLEN, BIANCA LEIGH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ONCO/RESOLVE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Marcus Assefa

MARCUS ASSEFA PERKINS COIE LLP3150 PORTER DRIVEPALO ALTO, CA 94304UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, buffers, and adhesive reagent labels, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being in the fields of scientific research, clinical research, and scientific diagnostics research; Biological and biochemical reagents used for selectively amplifying nucleic acid fragments for scientific research, clinical research, and scientific diagnostics researchACTIVE—
005Reagents and reagent kits comprising nucleic acids, naturally occurring and modified nucleotides, enzymes, buffers, and adhesive reagent labels, all for the purpose of preparing, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, regulations, transcriptions, and expressions, with the aforementioned reagents and reagent kits being for medical diagnostic purposes; Biological and biochemical reagents used for selectively amplifying nucleic acid fragments, with the aforementioned reagents being used for medical diagnostic purposes; Biological and biochemical kits comprised of diagnostic preparations for medical purposes, namely, for the diagnosis and treatment of cancerACTIVE—
009Computer software for the collection, management, and analysis of data for use in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; computer software for analyzing biological samples; computer software for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; computer software for use with reagents and reagent kits, all for use in detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; computer software for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processingACTIVE—
042Software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for collecting, managing, and analyzing data in the fields of scientific research, clinical research, scientific diagnostics, and medical diagnostics; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others for analyzing biological samples for medical purposes, namely, for the diagnosis and treatment of cancer; software as a service (SaaS), namely, hosting non-downloadable computer software for use by others with reagents and reagent kits, all for use in detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, scientific diagnostics research, and medical diagnostics; software as a service (Saas), namely, hosting non-downloadable computer software for use by others for bioinformatics and gene expression microarray image analysis, namely, gene expression quantification, gene image processing, and gene information processing; scientific research, namely, collection, management, and analysis of data in the fields of scientific research, clinical research and scientific diagnostics; providing biological sample testing services for others in the fields of scientific research, clinical research and scientific diagnostics; providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the fields of scientific research, clinical research, and scientific diagnostics research; genetic testing for scientific research purposes in the nature of providing bioinformatics and gene expression microarray image analysis services for others, namely, performing gene expression quantification, gene image processing, and gene information processing for others; medical diagnostic research, namely, collection, management, and analysis of data in the field of medical diagnosticsACTIVE—
044Providing biological sample testing services for others in the field of medical diagnostics; providing biological sample testing services for others for medical purposes, namely, for the diagnosis and treatment of cancer; medical diagnostic testing in the nature of providing reagent sample testing and diagnostic services for others, namely, detecting, sequencing, and analyzing nucleic acids and other biological molecules, samples of biological molecules, genes, genomes, nucleotide sequence variants and modifications, all in the field of medical diagnosticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 17, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 17, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 17, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 15, 2018EX1GSOU EXTENSION 1 GRANTED—
Nov 15, 2018EXT1SOU EXTENSION 1 FILED—
Nov 15, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 15, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 20, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 20, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 8, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 25, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 24, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 24, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 4, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 4, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 4, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 28, 2017DOCKASSIGNED TO EXAMINER—
Sep 28, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 26, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance